subretinal

Often subretinal fluid is drained as part of the buckling procedure.

This allows choroidal fluid to leak into the subretinal space.

The compact nature of the subretinal space imposes significant size constraints on the implant.

The subretinal space does not enhance with gadolinium contrast.

Some subretinal bleeding may be experienced and there is a threat of retinal detachment.

The anterior margin of the subretinal exudate enhances with contrast.

Optobionics was the first company to develop a subretinal implant and evaluate the design in a clinical trial.

Thus, subretinal implants often incorporate an external power source to amplify the effect of incident light.

However, some subretinal implants require power from external circuitry to enhance the image signal.

Additionally, subretinal implants enable subjects to use normal eye movements to shift their gaze.

The characteristic lesions are believed to result from a single nematode migrating within the subretinal space.

The subretinal membranes are of two types.

Other implantable devices being developed include those for the blind which are separated into two categories: subretinal and epiretinal.

In principle, subretinal implants do not require any external hardware beyond the implanted microphotodiodes array.

The subretinal placement is also more straightforward, as it places the stimulating array directly adjacent to the damaged photoreceptors.

A subretinal implant is advantageous over an epiretinal implant in part because of its simpler design.

Macrophages then migrate into the retina and subretinal space and digest the lipid.

Recent data indicates that the subretinal route may be subject to a greater degree of immune privilege compared to the intravitreal route.

Complications include subretinal neovascularization and pigment epithelial detachment.

Further work is required to link the observed ion transport changes to a reduction of apical, subretinal fluid absorption. 11.39 a.m.

This confirmed that the leaking vessels (subretinal neovascular membrane) had extended and the area of leakage was much closer to centre.

Thus overall, subretinal AAV is 5-10 times more efficient than delivery using the intravitreal route.

Subretinal injection of rd1 mice was carried out 4 days after birth, before the onset of rod photoreceptor degeneration.

Ophthalmoscopy frequently reveals creamy yellow-to-orange colored subretinal infiltrates.

The macula will have some retinal pigmentary changes and sometimes will have subretinal hemorrhages.